Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11343206rdf:typepubmed:Citationlld:pubmed
pubmed-article:11343206lifeskim:mentionsumls-concept:C0003320lld:lifeskim
pubmed-article:11343206lifeskim:mentionsumls-concept:C2004454lld:lifeskim
pubmed-article:11343206lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:11343206lifeskim:mentionsumls-concept:C0040557lld:lifeskim
pubmed-article:11343206lifeskim:mentionsumls-concept:C0596873lld:lifeskim
pubmed-article:11343206lifeskim:mentionsumls-concept:C1819433lld:lifeskim
pubmed-article:11343206lifeskim:mentionsumls-concept:C0439662lld:lifeskim
pubmed-article:11343206lifeskim:mentionsumls-concept:C0887947lld:lifeskim
pubmed-article:11343206lifeskim:mentionsumls-concept:C0150312lld:lifeskim
pubmed-article:11343206pubmed:issue11lld:pubmed
pubmed-article:11343206pubmed:dateCreated2001-5-8lld:pubmed
pubmed-article:11343206pubmed:abstractTextThe in vitro lymphocyte proliferative response (LPR) and interferon (IFN)-gamma production in the presence of Toxoplasma antigen were evaluated in 97 human immunodeficiency virus (HIV)-1-infected patients with CD4 cell counts of <100 cells/microL (group 1), currently >300 cells/microL but previously <100 cells/microL (group 2), or always >300 cells/microL (group 3) and in 28 non-HIV-infected blood donors (group 4), all seropositive to Toxoplasma. In group 2, 81% of patients had a positive LPR, versus 20% in group 1 (P<10(-3)). IFN-gamma production was greater in group 2 than in group 1 (922 vs. 0 Deltapg/mL; P=10(-4)). Multivariate analysis found a significant association between a positive LPR to Toxoplasma antigen and a CD4 count >300 cells/microL (odds ratio [OR], 16.3; 95% confidence interval [CI], 5.3-50.2) and anti-Toxoplasma IgG titer >150 IU/mL (OR, 5; 95% CI, 1.6-15.2). Immune reconstitution under highly active antiretroviral therapy was associated with a restoration of immune responses against Toxoplasma.lld:pubmed
pubmed-article:11343206pubmed:languageenglld:pubmed
pubmed-article:11343206pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11343206pubmed:citationSubsetAIMlld:pubmed
pubmed-article:11343206pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11343206pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11343206pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11343206pubmed:statusMEDLINElld:pubmed
pubmed-article:11343206pubmed:monthJunlld:pubmed
pubmed-article:11343206pubmed:issn0022-1899lld:pubmed
pubmed-article:11343206pubmed:authorpubmed-author:CharronDDlld:pubmed
pubmed-article:11343206pubmed:authorpubmed-author:DerouinFFlld:pubmed
pubmed-article:11343206pubmed:authorpubmed-author:AlbertiCClld:pubmed
pubmed-article:11343206pubmed:authorpubmed-author:FournierSSlld:pubmed
pubmed-article:11343206pubmed:authorpubmed-author:GanisF MFMlld:pubmed
pubmed-article:11343206pubmed:authorpubmed-author:MolinaJ MJMlld:pubmed
pubmed-article:11343206pubmed:authorpubmed-author:RabianCClld:pubmed
pubmed-article:11343206pubmed:authorpubmed-author:CarmagnatM...lld:pubmed
pubmed-article:11343206pubmed:issnTypePrintlld:pubmed
pubmed-article:11343206pubmed:day1lld:pubmed
pubmed-article:11343206pubmed:volume183lld:pubmed
pubmed-article:11343206pubmed:ownerNLMlld:pubmed
pubmed-article:11343206pubmed:authorsCompleteYlld:pubmed
pubmed-article:11343206pubmed:pagination1586-91lld:pubmed
pubmed-article:11343206pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:11343206pubmed:meshHeadingpubmed-meshheading:11343206...lld:pubmed
pubmed-article:11343206pubmed:meshHeadingpubmed-meshheading:11343206...lld:pubmed
pubmed-article:11343206pubmed:meshHeadingpubmed-meshheading:11343206...lld:pubmed
pubmed-article:11343206pubmed:meshHeadingpubmed-meshheading:11343206...lld:pubmed
pubmed-article:11343206pubmed:meshHeadingpubmed-meshheading:11343206...lld:pubmed
pubmed-article:11343206pubmed:meshHeadingpubmed-meshheading:11343206...lld:pubmed
pubmed-article:11343206pubmed:meshHeadingpubmed-meshheading:11343206...lld:pubmed
pubmed-article:11343206pubmed:meshHeadingpubmed-meshheading:11343206...lld:pubmed
pubmed-article:11343206pubmed:meshHeadingpubmed-meshheading:11343206...lld:pubmed
pubmed-article:11343206pubmed:meshHeadingpubmed-meshheading:11343206...lld:pubmed
pubmed-article:11343206pubmed:meshHeadingpubmed-meshheading:11343206...lld:pubmed
pubmed-article:11343206pubmed:meshHeadingpubmed-meshheading:11343206...lld:pubmed
pubmed-article:11343206pubmed:meshHeadingpubmed-meshheading:11343206...lld:pubmed
pubmed-article:11343206pubmed:meshHeadingpubmed-meshheading:11343206...lld:pubmed
pubmed-article:11343206pubmed:meshHeadingpubmed-meshheading:11343206...lld:pubmed
pubmed-article:11343206pubmed:meshHeadingpubmed-meshheading:11343206...lld:pubmed
pubmed-article:11343206pubmed:meshHeadingpubmed-meshheading:11343206...lld:pubmed
pubmed-article:11343206pubmed:meshHeadingpubmed-meshheading:11343206...lld:pubmed
pubmed-article:11343206pubmed:year2001lld:pubmed
pubmed-article:11343206pubmed:articleTitleImmune recovery under highly active antiretroviral therapy is associated with restoration of lymphocyte proliferation and interferon-gamma production in the presence of Toxoplasma gondii antigens.lld:pubmed
pubmed-article:11343206pubmed:affiliationDepartment of Infectious Diseases, Saint Louis Hospital, Paris, France. sandra.fournier2@libertysurf.frlld:pubmed
pubmed-article:11343206pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11343206pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:11343206pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11343206lld:pubmed